Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis.
Svetlana AgachiMarina I BeloukhovaDiane MouldMaria LemakSergey GrishinMikhail Yu SamsonovPublished in: British journal of clinical pharmacology (2024)
In patients with active RA, olokizumab potentially reverses the IL-6-mediated suppression of CYP3A4 and CYP2C19. According to FDA guidance, olokizumab is considered a weak inducer of CYP3A4 and CYP2C19.